BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL Post author: Post published:March 1, 2026 Post category: Continue ReadingBAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma Post author: Post published:March 1, 2026 Post category: Continue ReadingA Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
CMV-specific HIV-CAR T Cells as Immunotherapy for HIV/AIDS Post author: Post published:March 1, 2026 Post category: Continue ReadingCMV-specific HIV-CAR T Cells as Immunotherapy for HIV/AIDS
A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial) Post author: Post published:March 1, 2026 Post category: Continue ReadingA Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)
Cellular Therapy for In Utero Repair of Myelomeningocele – The CuRe Trial Post author: Post published:March 1, 2026 Post category: Continue ReadingCellular Therapy for In Utero Repair of Myelomeningocele – The CuRe Trial
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors Post author: Post published:March 1, 2026 Post category: Continue ReadingSafety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
Study to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa or Choroideremia Patients (ENVISION) Post author: Post published:March 1, 2026 Post category: Continue ReadingStudy to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa or Choroideremia Patients (ENVISION)
A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2) Post author: Post published:March 1, 2026 Post category: Continue ReadingA Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV) Post author: Post published:March 1, 2026 Post category: Continue ReadingA Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1) Post author: Post published:March 1, 2026 Post category: Continue ReadingA Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1)
